SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-260559
Filing Date
2020-10-01
Accepted
2020-10-01 08:15:52
Documents
5
Period of Report
2020-09-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d79040d8k.htm 8-K 34187
2 EX-4.1 d79040dex41.htm EX-4.1 109288
3 EX-10.1 d79040dex101.htm EX-10.1 265416
4 EX-99.1 d79040dex991.htm EX-99.1 10336
5 GRAPHIC g79040dsp067a.jpg GRAPHIC 2824
  Complete submission text file 0001193125-20-260559.txt   424735
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 201214514
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences